🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

János L. Tanyi

Penn Center for AIDS Research

ORCID: 0000-0002-5657-3698

Also affiliated with University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.5Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets

Nature Cancer(2021)10.1038/s43018-021-00282-w

Top 6%

3.5DataRank

Top 6%150 citations

Jiao Yuan, Meixiao Long, Junjie Jiang, Youyou Zhang, Tianli Zhang +10 more

Papers

Driven by 14 papers — median percentile 94. Top paper: “The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets”.

The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets

Nature Cancer(2021)10.1038/s43018-021-00282-w

Top 6%

3.5DataRank

Top 6%150 citations

Jiao Yuan, Meixiao Long, Junjie Jiang, Youyou Zhang, Tianli Zhang +10 more

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Nature Medicine(2023)10.1038/s41591-023-02452-y

N/A

2.2DataRank · unranked

106 citations

Marcus O. Butler, Roisin E. O’Cearbhaill, David Y. Oh, Melissa L. Johnson, Kevin Zikaras +10 more

Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102301

N/A

0.429DataRank · unranked

14 citations

Charly R. Good, Julie S. Barber-Rotenberg, Sangya Agarwal, Wesley V. Wilson, Alex Watts +27 more

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Cancer Cell(2021)10.1016/j.ccell.2021.10.008

N/A

0DataRank · unranked

197 citations

Riccardo Turrini, Aspram Minasyan, David Barras, Isaac Crespo, Alizée J Grimm +31 more

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.08.024

N/A

0DataRank · unranked

117 citations

Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin +17 more

Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets

Cancer Research(2021)10.1158/0008-5472.can-20-3458

N/A

0DataRank · unranked

6 citations

Jiao Yuan, Zhongyi Hu, Mu Xu, Youyou Zhang, Meixiao Long +8 more

Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry

PLoS Genetics(2020)10.1371/journal.pgen.1008641

N/A

0DataRank · unranked

118 citations

Kevin H. Kensler, Zhongyi Hu, Youyou Zhang, Tianli Zhang, Junjie Jiang +11 more

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2444

N/A

0DataRank · unranked

79 citations

Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan +14 more

H2Bub1 loss is an early contributor to clear cell ovarian cancer progression

JCI Insight(2023)10.1172/jci.insight.164995

N/A

0DataRank · unranked

7 citations

Priyanka Rawat, Hannah S. Rendulich, Akshaya V. Annapragada, Yasuto Kinose, Xiaoming Zhang +11 more

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study

European Journal of Gynaecological Oncology(2023)10.22514/ejgo.2023.002

N/A

0DataRank · unranked

12 citations

Tsung-Chiung Wu, E Barber, Minh Dao, Emese Zsíros, Renata R. Urban +8 more

Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

Cancer Cell(2025)10.1016/j.ccell.2025.07.005

N/A

0DataRank · unranked

24 citations

Fabrizio Benedetti, Aspram Minasyan, Mathieu Desbuisson, Paula Cunnea, Alizée J Grimm +37 more

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1602

N/A

0DataRank · unranked

32 citations

Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K. Weeks +16 more

Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment

Cell Reports(2020)10.1016/j.celrep.2020.107884

N/A

0DataRank · unranked

36 citations

Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yueying Wang, Nicki Loo +14 more

An NK-like CAR T cell transition in CAR T cell dysfunction

Cell(2021)10.1016/j.cell.2021.11.016

N/A

0DataRank · unranked

409 citations

M. Ángela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal, Greg Donahue +25 more